Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis
T Kalincik, EK Havrdova, D Horakova… - Journal of Neurology …, 2019 - jnnp.bmj.com
Objective Oral immunotherapies have become a standard treatment in relapsing-remitting
multiple sclerosis. Direct comparison of their effect on relapse and disability is needed …
multiple sclerosis. Direct comparison of their effect on relapse and disability is needed …
[PDF][PDF] Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis
T Kalincik, E Havrdova, D Horakova… - JOURNAL OF …, 2019 - avesis.hacettepe.edu.tr
Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis Page 1 1
Kalincik T, et al. J Neurol Neurosurg Psychiatry 2019;0:1–11. doi:10.1136/jnnp-2018-319831 …
Kalincik T, et al. J Neurol Neurosurg Psychiatry 2019;0:1–11. doi:10.1136/jnnp-2018-319831 …
Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis
T Kalincik, EK Havrdova… - Journal of …, 2019 - pubmed.ncbi.nlm.nih.gov
Objective Oral immunotherapies have become a standard treatment in relapsing-remitting
multiple sclerosis. Direct comparison of their effect on relapse and disability is needed …
multiple sclerosis. Direct comparison of their effect on relapse and disability is needed …
Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis
T Kalincik, E Kubala Havrdova, D Horakova… - JOURNAL OF …, 2019 - iris.unimore.it
Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis Page 1 1
Kalincik T, et al. J Neurol Neurosurg Psychiatry 2019;0:1–11. doi:10.1136/jnnp-2018-319831 …
Kalincik T, et al. J Neurol Neurosurg Psychiatry 2019;0:1–11. doi:10.1136/jnnp-2018-319831 …
Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis
T Kalincik, E Kubala Havrdova… - Journal of Neurology …, 2019 - avesis.omu.edu.tr
Objective Oral immunotherapies have become a standard treatment in relapsing-remitting
multiple sclerosis. Direct comparison of their effect on relapse and disability is needed …
multiple sclerosis. Direct comparison of their effect on relapse and disability is needed …
[引用][C] Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis
T Kalincik, E Havrdova, D Horakova… - JOURNAL OF …, 2019 - avesis.ktu.edu.tr
Objective Oral immunotherapies have become a standard treatment in relapsing-remitting
multiple sclerosis. Direct comparison of their effect on relapse and disability is needed.
multiple sclerosis. Direct comparison of their effect on relapse and disability is needed.
Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis
T Kalincik, E Kubala Havrdova, D Horakova… - JOURNAL OF …, 2019 - cris.unibo.it
Objective Oral immunotherapies have become a standard treatment in relapsing-remitting
multiple sclerosis. Direct comparison of their effect on relapse and disability is needed …
multiple sclerosis. Direct comparison of their effect on relapse and disability is needed …
[PDF][PDF] Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis
T Kalincik, EK Havrdova, D Horakova, G Izquierdo… - Psychiatry, 2019 - academia.edu
Objective Oral immunotherapies have become a standard treatment in relapsing-remitting
multiple sclerosis. Direct comparison of their effect on relapse and disability is needed …
multiple sclerosis. Direct comparison of their effect on relapse and disability is needed …
Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis
T Kalincik, EK Havrdova, D Horakova… - Journal of Neurology …, 2019 - jnnp.bmj.com
Objective Oral immunotherapies have become a standard treatment in relapsing-remitting
multiple sclerosis. Direct comparison of their effect on relapse and disability is needed …
multiple sclerosis. Direct comparison of their effect on relapse and disability is needed …
[引用][C] Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis
T Kalincik, E Kubala Havrdova… - Journal of …, 2019 - espace.library.uq.edu.au
Objective: Oral immunotherapies have become a standard treatment in relapsing-remitting
multiple sclerosis. Direct comparison of their effect on relapse and disability is needed …
multiple sclerosis. Direct comparison of their effect on relapse and disability is needed …